// App-Quantinova.ai

3224 : Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Sagar Lonial

Principal Investigators

  • Ajay Nooka

  • Praneetha Thulasi

  • Ashraf Z. Badros

  • Bennie H. Jeng

  • Natalie S. Callander

  • Douglas Sborov

  • Brian E. Zaugg

  • Rakesh Popat

  • Simona Degli Esposti

  • Julie Byrne

  • Joanna Opalinska

  • January Baron

  • Trisha Piontek

  • Ira Gupta

  • Reza Dana

  • Asim Farooq

  • Andrzej Jakubowiak

Medical Centers

  • Emory University, Winship Cancer Institute, Atlanta, GA

  • Emory Vaccine Center, Emory University, Atlanta, GA

  • University of Maryland School of Medicine, Baltimore, MD

  • Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD

  • Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Moran Eye Center, University of Utah, Salt Lake City, UT

  • University College London Hospitals NHS Trust, London, United Kingdom

  • NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London

  • GlaxoSmithKline, Upper Providence, PA

  • Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03525678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved